click contribut analyst
februari new york citi
capit market healthcar confer held februari new york citi year confer
set high standard particip level attende includ senior manag
compani approxim institut investor well estim manag one-on-on discuss
furthermor featur panel cover rang time critic issu affect healthcar sector includ
latest develop cellular therapi hemophilia hospit purchas migrain journalist bestsel
author michael lewi give keynot address
report capit market healthcar research identifi key theme expect investor focu
confer week across distributor equip facil manag servic
technolog sub-sector furthermor team provid central investor question present
manag team final chief us equiti strategist lori calvasina contribut perspect healthcar
space provid macro context view healthcare-ded analyst
conveni also includ full two-day confer agenda hope find report help
alway encourag reach research team discuss regard invest idea
tabl content
day agenda
lori calvasina head us equiti strategi
canadian
medic suppli devic
valu us dollar unless otherwis note
price market close februari et unless otherwis note
requir non-u analyst conflict disclosur see page
wednesday februari new york palac hotel new york citi present eastern standard time
break-out session immedi follow firesid present unless note
session
moder glenn novarro
michael lewi journalist bestsel author undo project flash boy moneybal blind side
moder kennen mackay
note present schedul minut panel present schedul minut present firesid format unless note compani present compani present format breakout take place immedi follow
present except note
follow compani host investor meet inc privat blackthorn therapeut inc privat cigna corp ci inc hansa medic ab hmed inc inc
thursday februari new york palac hotel new york citi present eastern standard time
break-out session immedi follow firesid present unless note
session
session
session
session
futur cellular therapi
david epstein former ceo novarti
pharmaceut current execut
chairman privat
moder brian abraham
session
luncheon keynot market strategi outlook villard ballroom
lori calvasina head us equiti strategi capit market llc
moder brian abraham
kennen mackay randal stanicki
session
session
note present schedul minut panel present schedul minut present firesid format unless note compani present compani present format breakout take place immedi follow
present except note
follow compani host investor meet inc privat blackthorn therapeut inc privat cigna corp ci inc hansa medic ab hmed inc inc
lori calvasina head us equiti strategi
leader earn
remain market weight analysi larg cap sector drive view
perform pick sector essenti in-line perform
year domin strong technolog leadership first six week health
one resili sector outperform broader
benchmark despit recent move major peak rel perform put place
sector august remain intact time market cap weight sector
within also bump fail clear past peak
valuat attract despit resili earli sector look
attract ev/ebitda forward price-to-earnings rel broader us equiti market
indic sit long-term averag though compel
valuat stori place current honor fall telecom stapl valuat
look much appeal see consum discretionari technolog
valuat larg cap health also meaning improv condit
place last year sector look overvalu ev/ebitda close fair valu
earn trend expect solid health isnt leader front
respect larg cap sector good report season
percentag compani beat consensu ep higher sector
percent compani beat consensu revenu hit new high
improv ep growth expect health sinc start year
far less seen financi telecom although ep
estim revis posit revis health sector rank
metric financi industri lead metric
dont see reason worri intrigu ownership/posit
perspect sell-sid net buy indic extrem elev
sector larg cap growth fund overweight posit
look extrem valu fund neutral hedg fund long eas back
short interest low point complac
strategi signal suggest provid servic interest rank industri
within biggest stock market cap earn revis sentiment/posit
valuat provid servic look appeal two four metric
pharma look best earn revis equip suppli least interest
group analysi neg score sentiment/ownership valuat
flow headwind health sector saw outflow worst
sector etf outflow continu good news outflow
lessen sever analysi suggest activ manag fund
drive outflow
fundament favor flat dont stand vs rest pack decemb
survey analyst fundament outlook coverag univers
analyst gener construct industri cover view
mostli unchang level bullish similar intens analyst
sector includ consum discretionari materi outlook also
lag analyst financi industri enthusiasm
health could benefit dollar strengthen think sector could
pressur yield curv steepen inflat expect pick usd
strengthen fear emerg among equiti investor earli februari market
pullback think sector could benefit due higher domest revenu exposur
trade histori vs usd sector perform posit correl
trend usd dont think sector would benefit yield curv
steepen inflat expect rise sector perform invers
correl trend yield curv inflat expect rise inflat
expect persist point concern among equiti investor
health trend growth trade past sinc bubbl
perform larg cap health rel broader market gener move
line growth/valu trade relationship broken bit recent
could due fact larg cap health longer heavili weight
growth valu
perform stronger small cap health larg cap health
health top perform sector small cap ytd also top perform
small cap sector gener rel perform uptrend sinc
decemb august peak rel perform remain intact
growth bia health persist small cap unlik see larg cap
small cap perform continu move sync growth/valu
trade health care weight continu much heavier small cap growth
small cap valu suggest growth appeal sector remain place within
hedg fund stake small cap climb examin hold
hedg fund singl stock market cap plu sector/industri etf found
hedg fund stake small cap stock percentag hedg fund
health hold hit new high rise rapidli sinc earli
sell-sid also highli bullish health small cap mutual fund
skeptic sell-sid net buy small cap health high end
histor rang extrem read see indic larg cap
health small cap mutual fund less construct growth
valu fund underweight case valu fund posit also near
small cap lack valuat appeal surprisingli given stronger run
perform small cap health look expens rel small cap univers
ev/ebitda forward price-to-earnings small cap health also look highli overvalu rel
larg cap health metric
health
outperform within
 far
though gain pale
comparison consum
discretionari
health rel
resili earli
sector essenti
in-line perform
clear leader
year non-
defens sector come
close benchmark
exhibit sector perform rel broader market
seen solid
perform recent
major peak leadership
rel
sector
gener
weight health
sector
tend top around
august
peak
chart right
compar valuat
profil major
sector one anoth
data captur
median sector
rel
calcul score
latest data point
illustr whether
high low rel
attract vs broader
market ev/ebitda
clearli attract
forward price-to-earnings
inexpens telecom
stapl much
compel consum
discretionari
rel broader
market ev/etbida
recent
return attract
even compel
forward price-to-earnings rel
broader market
far away
solid earn trend larg cap lack
percentag
estim top line
bottom line
high larg cap health
sector
report season
larg cap health
strongest
sector ep beat rate
exhibit percentag compani beat consensu ep estim
exhibit shift ep growth expect sector
sector seen healthi
increas bottom-up
expect sinc start
year
improv
noteworthi
weve seen
telecom financi
even improv
anticip growth rate
larg cap health
still lower
anticip
like sector
 major
ep estim revis
occur larg
cap
health
leader front
instead financi
industri
lead charg
highest rate upward
exhibit sector rank percent ep estim revis
rate upward ep
revis health
sector
howev indic
appear peak
sinc
earn revis
deceler stand
contrast sector
stapl
discretionari
rate upward revis
improv
sector remain highli
favor sell side
near high end
exhibit sale ep revis trend
exhibit russel growth benchmark fund averag overweight underweight
averag overweight
larg cap growth fund
elev though still
past peak
growth fund
briefli remov
weight return
progress
larg cap fund
less construct
health slight
underweight place
overweight underweight health
larg cap valu fund
neutral
remov weight
place earli
exposur risen
recent quarter
remain well past
exhibit russel valu benchmark fund averag overweight underweight
exhibit hedg fund overweight/underweight heath
us equiti strategi capit iq/clarifi weight hedg fund asset health singl stock etf rel
 sector weight hedg fund long posit captur via fund
short interest sign complac
exhibit short interest share outstand sector
short interest sector
continu decreas
near low end
histor rang view
sign
signal provid svc
intrigu group
improv valuat
attract
revis neutral
valuat
best sector
earn momentum
posit see
sign crowding/
interest us
expens valuat
evid crowding/
complac sell-
side short interest
indic note
view us equiti
strategi team
reflect view
sell-sid net buy near
past high equip
suppli point
crowd risk though
industri show sign
crowding/complac
indic
extrem one
rate upward revis
comfort posit
territori larg cap
deceler last
year peak seen
industri
revis trend
stronger
industri within sector
health seen etf
outflow earli
outflow abat
data
combin flow
activ manag
exhibit flow sector activ passiv etf
activ manag
health fund
extrem inflow
seen
strong enough off-set
outflow seen
health sector
 highli
own etf
sector like estat
util ownership
sector etf bit higher
growth-
technolog consum
exhibit percentag market cap own etf sector
exhibit percentag market cap own etf
appear sector longer one strongest fundament stori around
month sector scale bullish bearish
expos larg
cap industri
sector
market cap own
/earli januari
ask analyst score
fundament outlook
coverag next
month scale
weight
respons accord
market cap weight
industri
outlook health
posit
less robust
place financi
industri similar
intens major
discretionari
exhibit decemb analyst survey result shift fundament outlook
rang much construct much less construct
analyst get
bullish financi
industri come
along consum
sector view
contrast
rel flat similar
saw
compani health
revenu
outsid far less
materi
industri
deterior ism new order rise inflat
exhibit sale exposur sector
exhibit correl sector rel perform vs usd sinc
rel
tend move tandem
trend usd
suggest
strengthen
currenc would
accompani sector
like lag usd
within larg cap
univers
perform pharma
servic
close tie trend
estat telecom seem
like outperform
short term
perform
sector tend move
invers ism new
order sinc
relationship
place health
tell us sector
may benefit
defens play econom
condit lose
like technolog
growth trade
care perform
invers correl
trend yield
curv mean
like under-perform
exhibit correl sector perform rel broader
exhibit correl sector perform rel broader
exhibit correl sector perform rel broader
like technolog
perform
invers correl
trend inflat
expect mean
like under-perform
inflationari
post
bubbl era health
tend under-perform
growth lag valu
relationship start
break bit
favor valu
growth restrain
enthusiasm health
exhibit larg cap health rel perform vs larg cap
michigan expect inflat rate year univers michigan expect inflat rate year sector perf rel cap growth perform rel larg cap valu capit market healthcar confer preview
larg cap health longer style bia term market cap
larg cap space
measur russel
weight growth
valu similar
histor sector
heavili weight
health
within small cap
health best
perform sector small
cap
small cap
outperform sinc
decemb
perform vs
peak august bit
high
exhibit russel sector perform rel broader market
perform
continu trend
health continu
much heavier
presenc growth
exhibit health sector weight russel growth valu
sector perf rel russel cap growth rel small cap growth weightrussel valu weight
examin
percentag hedg fund
stock etf
suggest
hedg fund rotat
stock help drive
recent out-performance
space may due
percept
opportun small
health along
one main
way hedg fund
invest small cap
cap stake sector
high rel
sector high rel
exhibit percent hedg fund long posit invest singl stock
us equiti strategi capit iq hedg fund long posit via fund
us equiti strategi capit iq hedg fund long posit via fund
 small capz score sinc
short interest small cap
health pull back
high
net buy rate small
cap near
high end rang
even stretch
see larg
exhibit small cap fund benchmark averag overweight
underweight
health near low
end histor rang
benchmark
near long-term
exhibit small cap growth fund benchmark averag overweight
benchmark turn
slightli underweight
health low end
histor rang
overvalu rel
ev/ebitda contrast
see
larg cap
sector look under-valued
metric
exhibit small cap valu fund benchmark averag overweight
highli overvalu rel
larg cap health
look overvalu rel
broader small cap
univers price-to-earnings ex
contrast
see larg cap
sector look
under-valued metric
canadian
maintain mix outlook
overal mix year coverag univers predict
cours turnaround vrx continu past year term
debt new launch suspect persist overhang potenti drug exclus
loss could make difficult sentiment turn corner elsewher overarch
theme shpg broader hemophilia market on-going launch
disrupt potenti roch hemlibra beyond name expect clinic
regulatori and/or commerci progress within coverag pli to onc shift
payer mix commentari could prove headwind provid
highlight upcom catalyst company-specif object overview
oncolyt biotech inc onc turnaround stori driven
clinic result addit manag team
oncolyt biotech inc develop stage bio-pharmaceut compani explor
oncolyt potenti reoviru compani benefit concentr
metastat breast cancer mbc rather varieti area done previous
addit favour addit manag team improv investor
confid leadership firm lead product reolysin turn cold non-respons
tumor hot respons combin chemotherapi immuno-oncolog
agent specif compani explor reolysin ad chemotherapi
mbc patient ph ii trial patient treat reolysin
chemotherapi show median overal surviv month nearli twice
group receiv chemotherapi alon team prepar begin ph program
compani also announc region partnership adlai norty
chines base pharmaceut firm oncolyt intend pursu deal
form larg region global partnership year
promet life scienc inc pli clinic progress plasma-
deriv small molecul therapeut
promet oper biosepar busi year use
proprietari ppp technolog compani also small molecul therapeut divis
taken favour clinic step past year promet util separ
platform deriv therapeut plasma file bla pdufa april
compani first commerci product plasminogen treatment congenit
plasminogen defici plasma-deriv therapeut franchis sever clinic
stage program plasminogen wound heal ivig antitrypsin
novemb promet announc posit interim clinic data on-going pivot ph
ivig clinic trial treatment primari immunodefici diseas pidd
compani small molecul program led demonstr anti-fibrot activ
sever organ liver lung kidney heart current ph ii/iii trial sever
indic ckd alstrm syndrom ipf also expect public
moa near term respect peer-review journal could add credibl
fibrosi program compani look commenc pivot ph trial
studi nintedanib ipf posit ph ii result
inc to focus low-temperatur medic devic
focus often overlook increasingli import part health care
industri reduct danger infect acquir healthcar set
develop current sell proprietari low-temperatur medic steril unit
sterizon steril compani secur fda approv
steril label expand includ abil termin steril
flexibl endoscop four channel steril devic secur
approv termin steril flexibl endoscop four channel compani
pursu approv steril certain type duodenoscop elev mechan
later year sign global distribut agreement geting
industri leader infect prevent clean disinfect steril sinc
enter new agreement partner permit compani sell
directli consum north america
question manag
talk recent clinic progress made reolysin
timelin ph initi expect preliminari
benefit reolysin provid compar agent
recent sign region licens deal adlai norty provid
everyon detail partner terms/condit deal
provid overview futur partnership plan and/or opportun
hope list obstacl forese
go list
indic current pursu consid
briefli elabor collabor myeloma uk celgen
question manag
uniqu promet plasma separ technolog
announc accept bla plasminogen octob pdufa
date set april commun fda progress
ramp sale market effort ahead potenti launch
talk plasma-deriv therapeut and/or indic
plasminogen made clinic progress look
demonstr success ipf recent final ph
studi design elabor trial mechan action
make effect ad nintedanib
elabor timelin pertain ph initi
complet data read-out file ultim fda approv
indic pursu expect clinic
progress front
commerci plan also pursu partnership
plasma-deriv therapeut
step taken bring cash burn control also elig
prv upon plasminogen approv made progress find buyer
question manag
provid brief overview compani low temperatur steril
market opportun steril
make stand expect obtain extend
recent investor day feedback efficaci posit end-us
summar find
fda stanc steril market commentari
provid relev
commun fda rel frequent last six
month elabor discuss stage current
compani sever partner past geting recent
talk previou partnership work also discuss reason
behind recent chang arrang geting
compani ramp distribut and/or sale effort sort delay
think caus term devic placement
need chang way recogn revenu expect
detail recur revenu sinc control
coverag univers cover eclect mix healthcar stock med-tech
servic whole driven micro rather macro
differ perform name driven whole trade
perform clinic data/regulatori updat albeit combin risk-off
attitud favour profit defens name continu stick stock
strong fundament clear catalyst drive sharehold return
summari subsector brief review name attend
favour hansa medic molecular partner link recent initi attend
confer mereo biopharma indivior clear materi catalyst
bullish valuat remain attract neutral circassia
vectura neg morphosi link recent initi molecular partner
clinical-stag biotech differenti believ lead technolog
deliv antibody-lik product multipl benefit convent platform see
upcom datapoint significantli de-risk platform lead valuat
inflect point ahead
novel
immunomodulatori enzym present attract opportun within multipl
indic bullish approv within kidney transplant patient see valu
inflect point approach highd trial follow-on indic
upcom data point regul discuss
investor buy hansa
remain neutral btg convatec posit cureti sinclair pharma
attend confer posit sinclair pharma pure-play aesthet
confer continu well core brand silhouett soft ellans
recent turn profit spite recent issu partner almiral us
silhouett weigh heavili investor sentiment think current share
price could substanti upsid given us arguabl free option ii
valuat ex-u undemand busi gener revenu ex-u grow
 high margin gross valu sale
remain posit abcam consort medic clinigen attend confer
whilst neutral horizon discoveri recent dechra posit
clinigen pharma servic pharma product compani offer investor chanc
access grow market earli access/compassion use inexpens price
potenti signific upsid distributor choic unlicens
asset global scale think clinigen on-line order system cliniport alongsid
lead posit within manag access space could strateg enabl
strategi support platform hospit custom ii eu
question manag
seen meaning step competit divis recent
key forecast concerns/risk divis
mani hospit sign cliniport system
mani peer like cliniport system
fragment market early/manag access
top five prioriti group
believ brexit impact drug develop regulatori space
clinigen act benefit
key oper risk brexit
qp acquisit busi
thing gone well gone badli
plan foscavir gener appear letermovir launch goe
well take share quicker anticip
question manag
walk commerci launch strategi asset kidney
key develop prioriti platform outsid kt
fulli fund deliv launch see need
fund event
partner product territori receiv interest
incom request initi investig led studi new
corpor develop opportun look
recent discuss fda launch kt
much variabl treatment protocol expect practic
recent thought price asset per dose per
mani centr target kt us eu
kind patient share captur think let target
question manag
what darpin special darpin technolog
mani asset develop mani partnership
roch janssen termin collabor
anticip abicipar data show data demonstr
term efficaci safeti risk
would financi benefit molecular abicipar data posit
mechan action mani indic develop
expect efficaci data multi-darpin
data posit tri develop asset further/ partner out-
see potenti need capit rais circumst could
plan futur collaborations/ partnership
anticip delay abicipar launch case delay
think impact molecular
question manag
chmp come posit vote despit posit data delo
trial trial demonstr fewer patient treat raxon
need hospit system antibiot due lower airway infect
explain differ respons steroid non- steroid
user give us confid see differ effect sidero trial
wait sidero trial appli ema could
label look like us eu
chmp feedback dmd patient popul unabl receive/ resist
corticosteroid ii clinic rational treat dmd patient raxon
conduct anoth placebo-control trial repeat delo
submiss ema
take success second file
far interact ema committe provid
feedback design second studi request re-fil
share outcom expert panel design new trial
question manag
number train physician silhouett us continu progress
well think pull lower anticip
plan product us
take silhouett us right back chose launch would
independ launch look like capit opex expenditur requir
time-frame realist put infrastructur place
complet end-market analysi silhouett opportun
thought possibl still see true
eu key growth driver asset region basi
central cost busi break-even ebitda
row
market research complet ellans revenu asset
could gener quickli
much revenu think garner specif brazil
asset launch quickli
earli impress refin product acquisit happen
product us thermi relationship taken step back
clinic data point garner us approv ellans
much cost
summari view subsector coverag univers
order prefer
acut hospit investor sentiment toward segment low given string
earn miss first three quarter driven soft underli demand
environ grow concern impact prolifer high-deduct
consum driven health plan care coordin initi despit lack visibl
either stabil improv demand growth acut care servic tax
reform provid signific benefit earn cash flow lower-lev
name regardless outcom issu continu recommend
compani strongest balanc sheet lack company-specif issu solid
strateg execut abil take increment market share specif
manag consist last year mco continu enjoy strong underli
busi fundament earn visibl despit impact return hif
overal util commerci cost trend gener seem remain within even
expect outlook membership growth remain solid particularli
medicar book compani well posit capit deploy select
geograph activ vertic integr seem gain
momentum despit high expect segment believ posit investor
sentiment well place continu like particular posit
catalyst includ continu beat rais throughout medic trend develop
lower guidanc posit impact recent pass tax reform
possibl repeal return industri tax medicar extend bill legisl
earli final exchang stabil legisl pass could also mostli
optic catalyst sector potenti impact
univers notabl exchang exposur would expect stock price appreci
sector driven primarili earn growth rather multipl expans
behavior sentiment toward behavior segment
histor favorit among servic investor given stronger demand trend
lower capit need rel acut hospit turn skeptic late
company-specif issu industri fundament specif weaker
earn recent miss guide-down primarili weak result
uk oper repres approxim oper
recent seen softer util growth believ address fortun
appear demand issu head continu like
fundament industri outlook behavior industri given multipl demand driver
includ imd exclus rule mental health pariti act opportun help
address grow opioid addict issu us backdrop limit
industri capac growth shift sentiment reflect recent stock perform
current valuat like setup particularli given low
leverag strong free cash flow includ upcom benefit tax reform setup
oper year better volum growth benefit recent labor recruit
retent initi
health health continu gain favor among payor lowest-cost
set provid post-acut care given lower cost structur increas
capabl take technolog home home health play increasingli
import role transit away tradit fee-for-servic value-bas
reimburs believ busi posit well current healthcar
deliveri post-acut care well see deliveri care evolv time
beyond cost advantag consum prefer home health attract
strateg asset payor mco see home health anoth opportun manag
healthcar enrolle outsid higher-cost inpati set believ
consolid occur support higher valuat sector
hospic outlook hospic segment post-acut provid
encompass remain strong opinion expect
continu solid growth admiss censu well margin expans tight
cost manag appear appreci investor given posit
sentiment toward segment
outsourc hospit servic amsurg/envis merger experienc challeng
call activist investor along announc strateg review suggest us
reason chanc going-priv transact move would enabl compani
address challeng ed anesthesia segment away scrutini
public market potenti divest busi order better posit
long-term growth lbo rang seem reason
would surpris see scenario play near term
ltac rehab ltac result began reflect valid strategi
patient criteria follow short-term choppi relat initi
implement despit soft underli util environ may weigh ltac
volum continu view patient criteria attract long-term opportun
believ modest valuat receiv knd hospit busi ltm
ebitda aev/ebitdar see link going-priv transact reflect
company-specif challeng rather call industri meanwhil irf like
continu benefit among strongest underli volum trend healthcar
servic segment given attract demograph well-defin patient criteria
place year consist market share gain
senior live continu believ compel demograph
oper leverag increment occup posit senior live industri well
signific earn growth
competit new suppli growth certain market continu pressur occup
oper result least despit sever recent notabl larg real
estat transact attract cap rate senior hous sector
disconnect equiti valu impli public compani notabl brookdal
compani continu protract strateg review process could unlock
signific valu embed real estat asset see near-term multipl
expans absenc deal oncom suppli growth absorb
long term challeng
snf snf experienc signific oper headwind recent year
continu growth enrol neg impact censu occup margin
said see signific diverg perform
saddl high fix charg due lever capit structur
conserv financ uniqu extern growth strategi buy troubl
asset low valuat improv oper result time strong focu
manag balanc sheet optim portfolio remain key snf oper
dialysi underli oper environ dialysi steadi rel
subsector continu reflect pressur mainli mix shift commerci price
pressur larg public compani togeth control approxim us
dialysi servic market must look opportun drive growth
question manag
discuss posit respect on-going shift person care manag
shift value-bas
care payor person care fit
anticip move adjac home servic
much appetit home health asset among mco type
asset think mco would interest pursu part vertic
would character acquisit pipelin prioriti use
strong free cash flow light compani low leverag minim capit
note present compani cover capit market
question manag
hospic valuat remain level opportun less compel
growth strategi point think might go back
environ might caus valuat come time
anticip direct major free cash flow share repurchas
hospic industri penetr address market alreadi reason high
youv point reluct among patient famili
enter hospic last possibl moment keep industri median length stay
static day think ever drive number higher
revenu opportun
discuss regulatori reimburs outlook hospic see
potenti risk near intermedi term
expect vita high-acu censu mix eventu settl
declin past year anticip declin year
sustain yoy margin increas achiev
kind wage rate pressur see market
abl off-set
view long-term market growth potenti roto-root water
question manag
discuss vertic integr trend relat would consid
growth provid space home health hum/kindr
physician practic unh/davita medic group
would character competit environ commerci aso
look improv medicar star perform reacceler growth
book star crosswalk provis bipartisan budget act
impact outlook
guidanc assum medic cost trend
specif area anticip increas last year impress perform
see anyth yet would suggest uptick util
invest make use benefit tax reform
expect import acceler long-term earn growth trajectori
enterpris
initi thought recent announc partnership amazon
berkshir hathaway jp morgan see potenti eventu competit
threat aso book busi line
question manag
would character progress made thu far financi
restructur effort improv balanc sheet reduc fix charg
see sign relief market wage rate growth recent
quarter outpac reimburs growth
improv visibl earn relat medicar share
bundl payment improv initi exceed expect
thu far sustain out-performance next year
prospect expand particip value-bas purchas
question manag
result reflect strong sequenti improv volum increas
acuiti sustain think trend go forward
experienc term wage rate pressur market serv
strategi address pressur
area expect see focu invest effort servic line
expans addit access point
see use data artifici intellig evolv clinic
set next year discuss leader
develop
board initi regular quarterli cash dividend last month pleas discuss
action signal regard confid busi cash flow
opportun use excess capit
question manag
would character posit relat on-going trend
healthcar deliveri continuum prolifer value-bas payment initi
narrow provid network vertic consolid among health plan
provid updat streamlin effort divest non-cor lower-
margin oper whether effort continu redeploy
capit
pipelin potenti opportun look like
third quarter success complet refinanc lower
fix charg significantli improv financi flexibl potenti
acceler growth plan fragment imag industri platform
recent announc jv partnership larg integr health system
southern california includ capit arrang manag care
live would character level interest arrang
throughout countri
note present compani cover capit market
question manag
site-neutr payment provis bipartisan budget act directli
affect sem reimburs given near complianc rate see
chang impact ltac industri delay implement site-neutr
payment non-compli patient help keep struggl oper busi longer
potenti impact abil gain share
initi guidanc appear includ synergi us
healthwork acquisit recent complet transact
integr progress thu far reason nearli full-year
benefit expect gener cost save
revenu mix move ltac approxim result
recent acquisit concentra physiotherapi us healthwork
expect diversif post-acut area come year
staf issu physiotherapi locat alabama georgia arizona
maryland impact result play find success
hire new therapist accept full schedul patient
newer irf slower expect ramp
rel initi forecast
amazon overhang dissip drug price
drug suppli chain amazon ghost hide behind everi corner earli
though amazon made intent somewhat less opaqu announc
partnership jpmorgan berkshir hathaway start initi attempt
contain healthcar cost provid better custom experi press
releas broke amazon silenc news reveal amazon partner seem much
focus healthcar perspect employe beneficiari
oppos actual compet establish healthcar compani believ
mani drug suppli chain investor see news sign relief competit
amazon like enter drug suppli chain time soon suspect
could lead multipl expans drug suppli chain compani go
amazon-rel angst may subsid rhetor around drug price remain
loud ever presid trump budget propos took aim drug price
cost propos budget would creat new demonstr project would allow five
state creat medicaid drug formulari negoti drug price
manufactur budget propos also includ propos speed new gener drug
market would tweak rebat structur medicar part tri slow drug price
increas medicar part relat coverag univers think
chang benign manag though note meaning initi
govern negoti drug price could geni hard put back
bottl let
unfortun drug suppli chain see gener drug price continu fall
concentr buy group regulatori initi like one mention
continu exert pressur price gener drug price declin sharpli
pressur global purchas coalit reimburs pressur flood new
product entrant continu weigh acquisit retail price respons
pressur manufactur announc plan cancel product money-los
gener drug other announc facil ration ideal would
allevi over-suppli issu allow price stabil though believ
smaller gener manufactur may see opportun take market share
maintain pressur price price pressur compress margin absolut dollar
term across suppli chain
brand side expect see continu list price increas combin downward
price pressur brand drug exert payer regulatory/polit initi pbm
continu exert downward pressur brand drug price commerci book busi
variou formulari util strategi ahead budget propos
massachusett ask septemb feder permiss limit number drug
must cover medicaid spend medicaid chip increas
sinc passag could envis massachusett one first state
particip medicaid demonstr project initi becom law
lastli merger news domin healthcar servic space fail deal
includ anthem-and-cigna well aetna-and-humana sever larg health system
deal year-end announc cvs-for-aetna expect trend continu
though activ focus provid space payer
pharmaci space acquisit aetna bet futur vertic integr
consum centric valu base care deliveri model provid aspect model key
repres consum face touch end expect see expand
minuteclin franchis current store includ all-in-on clinic mani
locat believ vertic consolid could occur
expect year consolid occur provid side oppos
pharmacy-rel payer space due already-high level market consolid
expect continu affect space like focus
provid space tuck-in could view vertic integr expect
healthcar provid consolid continu given pressur industri face
payer rel fragment natur top system market increas
competit all-in-on clinic model push unh/cv govern
pressur rein healthcar cost believ consolid could look less
predict hospit system compet payer asset could
drive valuat asset-light uniqu provid base busi
believ industri consolid one biggest driver success/failur
hcit compani medium long term system consolid continu
atrium announc plan merg unc health
cathol health initi announc plan join digniti health ascens merg
provid st joseph health announc plan buy
provid group see wave consolid creat integr
standard tailwind incumb hcit compani newli merg system
like seek standard system trend believ typic benefit
vendor larger two combin hospit system compani cover
trend would benefit serv signific major ten largest health
system potenti expens allscript athenahealth expect
trend hurt retent rate vendor name epic/cern expect
decreas opportun new win number smaller hospit system
tradit like partner smaller hcit compani shrink
question manag
integr ei come along think
time margin ramp talk convers ei client
expect around retent churn
cross-sal opportun ei allscript recept
custom cross sell opportun product categori
fertil
pleas talk synergi allscript busi netsmart
busi advantag ownership netsmart busi
advantag disadvantag current ownership structur
expect decis singapor contract could made
larg contract would compar win australia
uk optum implement current stand
opportun partnership
seen meaning chang past year term competit
epic see epic come market
compet smaller hospit competit physician group busi
competit situat ambulatori talk differ
market segment competit athena ecw greenway qualiti system
look like va push hard interoper contract
chanc act kind tip point industri see significantli better
client decis make across industri seem slower past year
two seen remain trend could add urgenc client
purchas decis implement
impact delay mips/macra
current share custom use allscript host
expect next year
penetr rate patient portal interoper dbmotion
demand look like popul solut beyond patient portal
dbmotion
contribut solut like prior auth payer solut life
scienc clinic trial pharma relat solut
futur solut near avail thing like cloud
base ambulatori solut collect model
see provid consolid affect market share abil
question manag
start compani descript might know
could give us quick overview custom mix brand
manufactur biolog gener drug still develop level
outsourc compar segment
youv talk past finish drug product
initi stand keep expand aggress area
current outsourc rate among pharma compani
expect trend next year
still see larg number small molecul drug come
current capabl biolog feel like need invest
area overal revenu biopharma industri continu shift toward
pharmacor acquisit larg ad capac new
capabl came along acquisit
could go think declin largest product
free capac take product easi
redirect capac fill busi develop quickli
gener segment busi weve seen larg number anda
last year weve also seen pressur price gener manufactur
profit stronger influenc busi
market trend us compar trend intern market
growth rate cambrex compar industri growth rate
take market share custom drive custom chang api supplier
see indic gener manufactur might ration
product portfolio api purchas
expect effort limit suppli opioid painkil could drive growth
non-opioid product made api
concern regulatori effort limit growth whole control
thought intern capit deploy vs extern point
could talk impact declin largest product gross
note present compani cover capit market
question manag
start topic gener cardin less rel exposur independ
pharmaci gpo vs correct
rate gener deflat busi withstand still grow oper
earn right way think growth segment core volum
growth plu benefit share gain new launch off-set deflat
abl maintain gross dollar margin gener drug
model go forward
youv mention januari one largest month term price increas
activ recent price perform line expect brand
price sell-sid buy-sid differ gener categori
see develop go forward
talk cardin recontract dispens custom around multipl
worri polit impact price especi specialti project
doubl digit top-lin bottom-lin growth
profit brand drug longer tie inflat think
rate growth profit deriv manufactur see
proport chang sign new contract next coupl year
gave guidanc mention
earmark invest combat opioid crisi invest intend
deepen relationship current custom amount still right what
breakdown two initi develop
earlier year headwind client invest gener think
price concess earli renew still right way think
see util volum trend medic segment across
acut ambulatori home segment
think strong flu season affect pharma
cvss acquisit aetna affect red oak partnership
suspect deal would net posit neg volum
forese gross margin busi expand outgrow
custom brand specialti outgrow gener margin
peopl terrifi amazon risk suppli chain would
thought could impact home care edgepark talk
defend busi amazon risk
talk recent challeng glove busi cordi talk
differ headwind impact unit
integr patient recoveri busi cordi
capit deploy prioriti see price
asset attract market segment look
question manag
could walk us strategi biolog current state
outsourc biolog product talk competit environ
growth rate biolog busi prior cook acquisit
cook acquisit term ad capabl
capac manufactur biolog
kind runway cook acquisit give term biolog growth
need build capac
would mix revenu cook full capac
compar long-term target overal biopharma industri
cross sell opportun legaci biolog busi
much capac year expans madison add rel current
capac
softgel segment could give us detail impact recent
quarter consum health volum declin asia pacif one quarter
inventori adjust someth end market demand
much softgel busi compris
seem like accucap acquisit perform ahead expect
function intern accucap perform better expect
main driver expect flat revenu growth softgel
second half given strength accucap gener good north america
perform asia pacif
outsid biolog seem like busi posit neg
oral deliveri pre-fil syring well blow-fill-s
challeng could updat us perform part drug deliveri
drive need step enhanc blow-fill-s busi sinc
view rel recent product categori introduct
competit environ like clinic suppli servic seem like
area interest across compani cover pharma servic
differenti clinic suppli servic compani gener price competit
base servic capabl
reason busi long-term shouldnt follow growth clinic
trial wouldnt good proxi industri growth
driven strong growth ebitda segment fiscal
give us quick idea impact new account standard
css busi basic take revenu busi
real impact ebitda next fiscal year
big pull forward profit delay
mainten cook facil european pre-fil syring
question manag
probabl alway first question give us updat time
expect va contract
tell us anyth convers va may differ
see media
walk us expect financi contribut va contract
detail ramp expens tie va last call walk us
expens
give us first impress new ceo brent schaffer think
bring enter next stage life cycl
feel disrupt risk transit
propos trump budget fit expect relat
va contract billion alloc in-lin expect
issu budget would lower complianc hurdl
provid impact compani sale cycl
view outlook health system provid consolid
see posit could talk situat
compani win lose side recent
updat us competit environ inpati space
what composit new book term increas util
current custom vs bring new custom
talk opportun larg govern contract like coast
guard feder hospit even prison much landscap
book long-term contract see figur
chang next year
what outlook licens vs softwar servic
look season book go forward anyth chang
post complianc driven demand environ
much backlog expect convert revenu what averag lag
time chang
said expect tax benefit flow bottom-lin
expect chang
capit deploy prioriti repo back top tuck-in
acquisit make sens
question manag
seem like product larg new solut custom
sale process like look add new custom
level within organ typic make decis implement
solut inovalon
mani user typic first group begin use platform
compani compet sell typic ehr
data pull differ ehr system standard
valid could solut use interoper differ ehr
pharmaceut data given pull provid level payer level
data would seem complet data set larg compet
im sell pharma compani someth differenti
solut sell
iqvia talk fair amount prescrib level data valuabl
clinic trial enrol work use data clinic trial
identifi physician could help patient enrol
could talk current adopt rate client averag
number compon modul client use
go forward expect cross sale compon new client adopt
bigger driver revenu growth
balanc inovalon intern term analyt vs
provid data custom let drive analyt
expect long-term expens growth rel revenu growth
start see oper leverag line go forward
major benefit youv seen avaler acquisit
realli leverag strength busi drive better result
share busi come subscript base model
expect maximum get
note present compani cover capit market
medic suppli devic
favorit idea
retain bullish view med-tech sector large-cap med-tech favorit
growth idea remain ew growth reason price investor
recommend remain favorit valu pick smid-cap
pick includ ktwo
sector thought key theme
major end market remain stabl base recent channel check proprietari survey
attend major medic confer meet manag team
result believ end-market cardio orthoped capit equip remain stabl
respect volum price continu recommend overweight posit
cardio see new product cycl drive faster growth especi
ew believ ww drug-elut stent market remain stabl help
new product launch favor replac cycl expect ww
tavr market grow favor ew also believ investor
remain overweight orthopedic/spin channel check indic stabl util
trend knee hip posit
exhibit call group
 continu expect compani
remain activ minim debt leav plenti room use balanc sheet
 primari capit alloc strategi deliv competit dividend
expect compani activ front similar last year invest
 hint strong appetit tax reform fuel
 activ view acquisit prefer use cash
med-tech valuat look attract post recent market sell-off jan jan
large-cap med-tech ralli howev recent sell-off market wipe
away major gain ytd large-cap med-tech lag
recent sell-off group believ creat attract entri
point med-tech investor large-cap current trade forward price-to-earnings
jan slightli three year averag
smid-cap med-tech stock perform lag large-cap
exhibit large-cap med-tech ytd trade slight premium
large-cap med-tech stock appear valuat support
ew lost gain ytd trade three-year
averag forward price-to-earnings multipl believ stock offer attract entri point
current trade forward earn three-year averag
limit downsid opinion believ market-wid sell-off ignor
jnj pharma segment remain growth engin pipelin contain sever
blockbust contribut strong pharma growth jnj balanc sheet
give manag flexibl supplement organ growth buyback
current trade three-year averag believ
current valuat limit downsid meanwhil believ remain track
deliv mid-single-digit revenu growth owe acceler growth
diabet pain therapies/spin cord stimul spine continu strong growth
tavr dcb de af
similar large-cap med-tech idea ew current trade three-year
averag believ limit stock downsid like ew mid-teen tavr
growth option exist mitral tricuspid pipelin
question manag
recent discuss see pickup radiat oncolog market growth
give us updat health us eu apac radiat oncolog market
well linac price dynam expect market growth
talk upcom technolog compani
compet market newer system elekta becom
versatil reach across modal
think sale funnel ramp radixact particularli light
upcom tomotherapi replac cycl radixact launch met exceed
disappoint rel initi expect
competit impact seen varian recent launch lower-end
halcyon system launch led tomotherapi replac bunker
takeaway varian
compar contrast technolog capabl radixact versu
varian halcyon system radixact prefer halcyon
regard cyberknif provid sens percentag instal base
upgrad compani drive addit upgrad
revenu compani actual declin y/i despit past high-single-digit y/i
increas gross order discuss work compani alreadi done
improv order revenu convers metric still left done
america region one region particular under-perform prior
quarter discuss improv perform region
confid improv america region
ramp onrad launch china disappoint thu far discuss
sale funnel onrad progress light class quota uncertainti
provid updat class quota situat china discuss
progress regard potenti chines partnership jv
discuss upcom softwar hardwar technolog
excit radixact cyberknif think
time new technolog
view broad commerci adopt could mr-linac
system concern could crowd invest higher end
tomotherapi cyberknif system
compani analyst day adjust ebitda margin target
expect year compani end ebitda margin
target laid analyst day still reason given recent setback
revenu front compani updat long-term guidanc
one big differenti varian market right strong softwar
offer recent launch new treatment plan system partner
raysearch oncolog inform system strategi longer-
term remain competit softwar front compar larger player
like varian elekta
question manag
lot focu margin expans compani recent set non-
oper margin target key driver get
current area could repres sourc upsid
target
manag progress non-gaap oper margin larg surpris
upsid past sever year less upsid surpris
revenu growth front discuss key product see drive
acceler revenu growth
talk upgrad come spectrum infus pump timelin
opportun compani next gener infus pump us
discuss abl capit issu braun
solut price gain bax iv solut busi
give us visibl timelin new product launch
inject market opportun may address new
make organ invest biosurgeri busi provid
inform new product expect could acceler
revenu growth categori
discuss opportun renal largest product opportun
focus compani amia prismax
product launch theranova clinic trial
busi within believ more/less like benefit
next coupl year key metric focus
compani done lot past month
hold deal focus smaller tuck-in deal would
discuss competit dynam market cyclophosphamid supran
expect new competit
think amazon futur potenti competitor
hospit suppli space think success
talk bax recent decis acquir two hemostat sealant product
recothrom preveleak believ product
add bax advanc surgeri product portfolio
discuss next develop step system advantag market
opportun new home-bas periton dialysi pd solut system
expect submit fda
question manag
metric manag team look give confid
cynosur busi turn around compani maintain
ep accret guidanc despit lower sale outlook
discuss market opportun recent sculpsur subment indic
well recent launch tempsur envi product us
talk compani drive sculpsur monalisa touch
penetr ob-gyn channel pushback get ob-
gyn dont want purchas bodi contour system
big futur growth area compani discuss see
near-term growth opportun intern market see
product/market develop effort take longer intern market
tomosynthesi competit ramp us ge siemen fuji
discuss holx strategi continu take share market competitor
launch system differenti featur
provid insight futur upgrad pathway tomosynthesi
talk revenu ramp new brevera breast biopsi system
differ affirm prone product
discuss posit viral load portfolio versu larger player like
roch learn viral load launch europ
talk thought holx futur genom companion
diagnost two fastest grow part diagnost market
get readi launch hpv assay us discuss competit
threat view largest competit threat holx molecular
diagnost busi near-term
talk outlook thinprep busi particularli light
recent draft uspstf guidelin cervic cancer screen
gyn surgic busi struggl recent talk
drive weak manag address weak
competitor gain share novasur recent
manag stem recent declin busi
help us size potenti market opportun myosur much
market opportun believ alreadi captur
gyn surgic bag current product look like ripe area futur
 difficulti find product outsid compani add
market could area futur opportun
talk opportun left cost save compani term
manufactur facil footprint structur cost
compani gener oper cash flow annual basi
talk expect use cash term debt repay
capital-expenditure share repurchas next sever year
question manag
besid increas quota-carri rep market zio market place
strategi goal go compani focu pursu
intern opportun compani plan upgrad exist product
line compani pursu expand product capabl new
latest statu hire new quota-carri sale rep mention
prior call rep per quarter good goal youll reach goal
hire quota-carri rep end mani plan hire
hire front/back load spread evenli throughout year
still model peak sale product per quota-carri sale rep
expect increas assumpt near term
zio sell market place see help drive sale
xt
latest reimburs coverag compani expand coverag
peopl
thought earli read-out mstop diagnost high
expect full read-out mstop still expect spring
updat intern opportun focu europ asia
think size market
what view competit seeing/hear new entrant
market thought wearabl fit product way
team manufactur
question manag
forecast oper revenu growth rang organ
growth basi point less key variabl determin low
high end rang compani better rang
revenu growth weight first half second half year
past year complet major transact three
report segment time compani activ divest non-
core low growth asset look ahead next coupl year major
chang forese jnj corpor strategi especi avail
organ growth outlook pharma segment next year
mega-blockbust track compani intern forecast
major line extens brand like receiv approv
time-frame
zytiga give confid fend gener competit
year potenti offset event effort defend zytiga ip
cardiovascular franchis payer commun demand higher price discount
certain key brand especi invokana/invokamet xarelto headwind
continu worsen manag off-set impact faster volum growth
big impact see compass result peak sale xarelto
price drive sale growth volum price
price increas probabl see
definit legisl action pharmaceut price year
pipelin late stage compound nme line extens
excit key mileston watch next
medic devic jnj devic segment post revenu growth mani peer
oper revenu growth anem orthoped surgeri
think two franchis segment gener
consum segment viabl segment long run compani
better serv focus pharmaceut medic devic alon
consum remain viabl segment expect improv financi
perform face sustain competit pressur
oper margin much room improv remain given price
pressur three segment busi margin improv split
across variou expens line
incom line becom quit big make signific
contribut earn confid
manag transact
contempl guidanc year complet schedul
risk ep guidanc oper expens adjust time
question manag
thought us spine market market trend
compar
believ led recent slowdown us spine market
give confid us market growth pick
provid us updat market share captur becom
difficult take share larger competitor johnson
recent select new distributor japan provid updat
new relationship go new distributor contribut
provid updat rhine cervic disc progress
europ provid comment could expect see
introduct us market
provid us insight leverag relationship
brainlab unit instal base mani account current
product opportun largest revenu growth
driver ktwo
discuss bac platform featur platform surgeon find
interest ktwo get compens technolog
talk market opportun mojav expand cage part
talk outlook ktwo australian market
recent govern implant price cut impact australian spine market
recent announc ktwo australian distributor could go privat
discuss believ impact ktwo
robot spine appear take multipl competitor either alreadi
market process develop system ktwo address robot
talk still see product gap opportun either implant
biolog side ktwo
outsid japan australia intern market repres largest
near-term growth opportun ktwo
sale rep turnov trend past month ktwo becom
difficult expens on-board top distributors/rep
provid updat product new sale rep
ktwo still deliv doubl digit ww revenu growth market flat grow
low-single-digit y/i assum ktwo turn profit
question manag
discuss us market train strategi senhanc mani sale
rep expect year-end
hospit trial senhanc us europ decid
purchas system pushback system
differenti factor senhanc versu isrg da vinci system
what left senhanc registr intern market
aggress compani expect invest us vs europ
instrument current avail senhanc work
senhanc wrist instrument capabl compar intuit
strategi senhanc data/research gener us europ
cost/timing/structur futur clinic studi senhanc
select run studi
size senhanc system compar da vinci si/xi older
oper room abl hous senhanc system comfort
path forward surgibot us europ senhanc
discuss valu proposit senhanc versu da vinci si/xi
system servic averag instrument costs/cas compar
think senhanc growth come take busi
away expand market
announc valid syk camera platform novadaq pinpoint
platform senhanc technolog valid other
next term enhanc senhanc platform
plan combat upcom surgic robot titan
medic verb surgic due compet surgibot next year
discuss expect quarterli cash burn rate
compani may need rais addit capit
compani expect develop stapl devic robot surgeri
discuss mani surgeon train clinic leadership
program thu far plan expans program addit clinic site
talk competit respons see european
hospit trial senhanc system think make compani
success compet market domin entrench player like
neutral gener fundament favor specialti brand
last two year challeng specialti pharmaceut see thing
get increment better two main chang view
bullish brand low tax rate high short interest elev risk
discount help drive better perform ii less bearish gener
sector enough call bottom argu materi upsid
number theme focus confer year
theme focu fundament gener less bad earli revers
expect see gener sector pressur persist us also believ worst
behind us expect better align realiti gener price final
show sign stabil expect elev eros level persist
forese futur likewis expect ramp fda approv remain headwind
although impact could partial mitig complex gener approv overal
earli tone mix compani point potenti
bottom us gener price other remain pessimist
theme leverag remain signific overhang mani
high leverag multi-year theme follow roll-up invers year
expect continu high leverag driven lot investor debat
appropri leverag level larg brand player want see
leverag gener manufactur messag need remain debt
reduct take longer other leverag come
difficult execut large-scal strateg though equity-bas deal merger equal
may possibl
theme still plenti neg headlin start fade bit
less concern drug price legisl concern residu
headlin risk gener drug price fix opioid litig opioid scrutini continu
pick expect benefit opioid-altern play pacira flexion
compani lever opioid neg headlin continu pressur volum mani
navig on-going litig congress yet complet appropri bill
feder budget earli sign includ presidenti budget indic minim impact
coverag
theme black swan structur surpris keep watch
given reset sector dynam new norm follow consolid buyer
altern distribut becom increasingli import debat amazon teva
anda unanim agre upon fourth buyer would increment
posit time unclear also note impact like limit near-term given
vast major gener drug purchas three consortium
discuss around whether consolid buyer anti-trust concern
though expect scrutini pick expect meaning action take place
question manag
primari feedback type meet fda januari
dsuvia two recommend discuss
anyth unexpect discuss meet conclus
need conduct anoth safeti trial analysi exist data includ
need conduct anoth safeti trial would look like
timelin much would trial cost addit data fda want around
safeti could address without addit studi
next step human factor studi alreadi underway
timelin refil dsuvia
exampl crl request safeti revers
case could happen dsuvia hospit use increas
scrutini opioid perhap fda cautiou
dsuvia hospit use administ healthcar profession
heighten scrutini opioid push hospit decreas usag
expect potenti adcom either zalviso resubmiss dsuvia
zalviso refil delay dsuvia meet conserv
follow meet manag confid read-through
dsuvia addit data might need includ
file refil
think launch trajectori zalviso impact
abil co-promot dsuvia expect on-board rep earli
discuss gone committe focus cost
updat expect around cash guidanc cash burn expect stay
rel stabl would launch spend start take place much would
human factor studi anoth safeti studi need cost lever
pull access cash
pantheon readi zalviso approv manufactur standpoint
everyth prepar launch assum approv
question manag
prepar discuss second indic cosyntropin
plan announc addit indic think timelin
market thought commerci strategi
nucynta handoff collegium complet disrupt sale
abl talk life-cycle collegium deterx technolog
statu cebranopadol still move forward clinic
develop phase initi late could see anoth creativ transact
involv asset
plan headquart reloc track plan close select new
locat morale/employe retent follow announc layoff
think time
provid updat purdu litig likelihood
settlement outstand litig investor awar
start search new cfo plan ensur smooth
transit hold busi develop new team
type busi develop pursu commit
ad least one new product commercial-readi asset
stage develop look import find product
leverag exist sale forc
pipelin product develop much focu place
intern would partnership opportun interest
much differ made dedic field forc gralis
cambia chang payer environ enter
abl improv part coverag gralis
question manag
tail valu bendeka given competit landscap ie murano data
much impact bendeka high awar data
commun oncolog set better efficaci compar rel
titrat period learn curv proport patient bendeka
eh discuss fda around
feedback discuss without path forward
import area disagr next step forward
think anoth trial eh would look like
would cost trial long would take complet disput
read-through eh dih ryanodex label expans
level awar around eh dih think
launch trajectori given level educ need
mani patient enrol dih trial thu far trial
fulli enrol expect data eagl increas
enrol hit target updat around nerv agent label
mani patient enrol fulvestr thu far late april
complet still possibl enrol
uniqu j-code still like fulvestr opportun look like
without
latest updat around pemfexi much market eagl take
differenti rtd liquid
strateg capit deploy prioriti near-term busi
develop opportun compel much financi flexibl
eagl
question manag
give earli color commerci launch zilretta knee oa
doc feedback like thu far seen greater uptak rate diabet
patient import zilretta posit non-opioid physician
convers metric focus report result
commerci payer discuss go physician success
get reimburs wont get j-code januari step
taken mitig success
report posit initi data on-going repeat dose studi earlier year
import get repeat dose label timelin
doc feedback around repeat dose
youv state your aggress seek in-licens candid
chanc see announc sometim year stage develop
consid type product target biggest hurdl
complet deal
recent initi phase studi oa hip shoulder could see
phase studi next year would cost joint look
potenti time get label expans
start shift focu ou promis region would
look partner form might take would path ex-u
approv launch
much focu devot clinic pipelin statu
intern candid hold particular promis
much runway cash on-hand much flexibl
question manag
statu doj investig given enter year
rel prior guidanc year delay due chang administr
someth els hold resolv year
goal post around settlement goal post chang
last year insi accru best estim minimum liabil exposur
think rel settlement could
non-cash part settlement import
analogu look would help latest updat around
state investig could conclud
tirf class continu pressur y/i declin high mid
could begin stabil stabil despit continu scrutini around
opioid could worsen
primari driver share loss last year
addit manag care contract initi support patient
launch yet help inflect script els need done
see turnaround still expect top line growth given assum
stabl subsi grow syndro subsi bigger piec script still
declin gross net year take anoth step
syndro initi feedback launch there
conserv view launch acceler meaning
peak sale expect syndro much relat
label expans opportun much requir convers exist
market vs grow market updat label expans opportun
time agit associ alzheim well anorexia associ
condit aid
right level progress pipelin forward also balanc
potenti near-term cash need settlement continu declin
subsi need restructur sale forc right-siz despit declin
sale given syndro launch buprenorphin later year
potenti peak sale buprenorphin
phase infantil spasm cannabidiol oral solut initi yet
studi look like timelin
question manag
confid apadaz approv februari feedback
like potenti pharma partner pbm two path market
explor willing purchas larg volum price gener
decid specif path market think cash flow
potenti partnership
much runway cash on-hand kind lever
pull delay pipelin approv expect chang
cadenc cash burn go forward
enrol go pivot efficaci studi still track
read kind share could drug take broader adhd
market start think launch strategi might
approxim one year behind impact strategi
plan leverag develop program clinic studi
expect initi pivot efficaci studi
similar studi recent adhd launch target adult
strateg intent plan develop
would consid strategi allow focu adhd besid
apadaz pain candid commerci potenti kind
label would need see get meaning penetr
competit environ look like adhd competitor
drug develop your watch pain
announc partnership agreement genco scienc octob
opportun licens partnership deal find compel
near-term intend focu adhd/cn would consid addit
question manag
commerci progress around launch percentag
target ent allergi specialist clinic nurs educ cne
reach prior launch initi doc feedback like launch
ramp look like revenu perspect expect growth hit
initi discuss payer timelin
expect coverag target tier payer coverag single-step
edit prior author play success would consid
scale number sale rep base payer coverag launch
track initi phase studi chronic sinus without polyp later
year much dialogu fda import
indic compani success trial structur similar phase
studi nasal polyp
start shift focu ou promis region would
look partner form might take would path ex-u
approv launch
much runway cash on-hand expect spend
ramp launch kind balanc sheet flexibl
interest pipelin opportun much focu plan
put earli stage pipelin next year
biggest thing could go wrong launch prepar
big threat monoclon antibodi expect see hit
market treatment develop could challeng xhanc
road
question manag
confid around path approv pdufa come april
given fda typic follow adcom decis doesnt alway
prepar sale rep market new indic upon approv
pacira rep alreadi larg start switch focu soft tissu opportun
synergist label expans increas soft tissu penetr
much contribut nerv block
expect around market size penetr
hurdl gener entrant follow draft guidanc
pacira think unlik see entri gener start today long would
take readi launch
cost hurdl potenti gener would abl either adjust
exist facil creat commerci scale manufactur requir fda
altern leverag anyth els player would
capabl creat gener
alreadi start see lift dp
think type growth see ortho side
busi rel soft tissu side
off-cycl j-code still possibl opportun exparel given
separ j-code much tailwind would unbundl hospit
custom said anticip uptak see unbundl
pacira activ washington import high-level tailwind
discuss go think thing move ahead
updat commiss combat drug addict
opioid crisi lobbi effort help
import opioid spare convers hospit heighten
opioid scrutini play versu immedi cost compon
type hospit partnership announc expect hear near-
term think quantifi type opportun like triniti
compel busi develop opportun seen
could see potenti deal near-term pacira still aggress evalu
opportun oral surgeri walk us partnership
aetna aaom could pacira pursu deal player similar ortho
deal drive penetr ultim big market could
biotech cautious optimist continu sector
momentum given like persist tailwind off-set
number key headwind still investor mind believ
activ continu draw generalist back sector sustain sector momentum
key catalyst investor view continu sector growth year-
end return generalist capitalist elud space sinc drug price concern
emerg expect drug price remain investor radar
believ posit sentiment especi heel tax reform
could catalyz sector draw generalist back space
exhibit estim sector positive/neg driver left vs investor expect right
capit market biotech outlook investor survey
anticip drug price rhetor return approach mid-term
elect inde seem occur though believ increas
investor toler headlin risk recent polici propos look less unfavor
sector previous perceiv re-emerg drug price polici discuss
trump administr recent white paper budget well
senat budget resolut larg expect reignit drug price concern
though investor resili headlin risk maintain
polici propos far fairli top-lin legisl initi would need
sign congress devil detail execut still
believ propos provid framework govern intend tackl
issu provid public investor view line across
intend promot effort drug cost contain continu drive
price policytax reformregulatori landscapesentimentfinanc environmentearn growthm apat cliffstherapeut area emergenceinvestor select biggest posit neg driversbiggestheadwind neg driver biggesttailwind posit driver averagebiggest tailwind driver biggest headwind -driver
strong balanc sheet need growth/pipelin among larg biotech pharma
tax reform clariti creat recip increas saw larg biopharma
wrestl need chang narr slow ep growth pend patent
cliff combin low interest rate cash posit highest
point year creat environ prime deal-mak far weve seen
two high-profil acquisit bivv juno list potenti mid-/large-cap target
investor survey
exhibit investor select like takeout mid-/large-cap takeout candid
capit market biotech outlook investor survey
believ addit deal flow still necessari draw generalist sector
materi howev total deal valu transact exceed
alreadi track exceed prior year peak
think like occur compani due dilig transact term discuss
matur throughout year
risk around remain deal expect high limit near-term accret
opportun high valuat potenti greater focu partnership larg
merger vs tradit biotech acquisit would like add investor frustrat
lead exit group
favor regulatori landscap new therapeut class
highli favor regulatori landscap continu fda gottlieb continu aim
implement centuri cure act increas number acceler approv base
surrog endpoint eas path approv drug expand new indic
addit launch new product class cgrp therapeut modal
 car-t gene therapi underpin biotech abil maintain top-lin diversif
organ growth base busi come increas threat emerg
competit also bring focu attract growth opportun next frontier
medicin
biotech top large-cap long idea
celg think sentiment bottom celg concern revlimid ip
abat revenu bounc back potenti deal pipelin start
come investor return name best-in-class growth
also continu like soliri expans mg broad label
likelihood success ph iii pnh program back best-cas pk
support efficaci data seen street may view
probabl success binari view compel ph pk/pd data support
attract risk/reward read-out
biotech top smid-cap long idea
remain bullish increas confid idhmut franchis
potenti wholli own ivosidenib follow rapid approv pathway
celg/agio idhifa larger market frontlin aml agio pkd franchis add
anoth wholli own shot goal rare diseas potenti global peak sale
beyond pkd idhmut aml franchis mtap program
worth watch potenti target genet mutat occur
aldr follow remov key overhang financ ph iii data ip settlement
view share significantli de-risk believ launch competit
product highlight larg cgrp antibodi space think
catalyz appreci addit setback competitor program could
like peanut allergi sever asthma read-
out remain posit toward mechanist rational
larg attract indic note potenti first-in-class
chronic prophylaxi adult peanut allergi best-in-class sever asthma via
broad differenti efficaci regardless eosinophil statu
question manag
help us understand diminish effect urin heparan sulfat hs
urin gag seen recent mps-iiia dataset world
anticip csf hs follow similar pattern urinari hs import
read-through would durabl longer term neuro-cog effect
expect neuro-cog data evolv move forward vs natur
under-perform patient cohort recov ill could
perform studi affect go forward
import efficaci paramet organ
age confound neuro-cog data seen date age would
late treat base natur histori data
compel singl patient data vs natur histori competitor
expect data deepen time could see
diminish
might abl better mitig unrel confound factor
evalu neuro-cog data futur
design registr trial number patient enrol
mani graft patient receiv endpoint
compar contrast
thought price
re-treat scheme
estim cog produc therapi
view pre-exist antibodi capsid nh studi result
shown incid kid age year adult
expect rang therapi becom
long think efficaci sustain
pre-clin data inform
level durabl see commerci attract viabl
talk plan address outstand ip issu
make confid abl obtain licens
specif data expect see asgct
question manag
run assumpt regard probabl
palisad peanut allergi studi read success high particularli hit
pre-specifi requir lower bound ci competitor
dbv unabl meet
suspicion regard dbv fail despit show
walk us key differ trial vs dbv especi
relat baselin patient characterist differ endpoint measur
outlin might see top-lin press releas relat efficaci
event hit lower bound ci view
path forward would argument press forward submit
view safeti bar given safeti signal eosinophil
esophag seen factor might play go
posit vs competitor viaskin peanut patch anab
view potenti market penetr curv s-curv fast uptak slow
view market opportun rel current util trend
homebrew oit think avail fda-approv product could
disrupt dynam
bar entri oit market low strategi undertaken
undertak protect posit
help us understand ip landscap
next step gate factor transit next codit product
clinic
question manag
base knowledg event rate expect mace event
rate control arm two studi
discuss potenti vadadustat show superior mace two
power assumpt protect trial non-dialysis-depend
ckd innov trial dialysis-depend ckd
comment risk treat ckd patient hif-ph inhibitor given
frail natur ckd patient consid hif-ph novel mechan potenti
oncogen cardiovascular risk
comment differ safeti profil vadadustat non-
dialysis-depend ckd patient vs dialysis-depend ckd patient
explan higher death rate observ ndd studi
think baselin characterist seen dd studi repres
gener patient popul set
see vadadustat compet hif-ph inhibitor space potenti
market entrant behind roxadustat
differ efficaci safeti conveni etc see vadadustat
competitor
could variou lcm initi liberti forward help differenti
walk econom partnership agreement mitsubishi
tanab otsuka rational priorit royalti vs up-front cash
vs cost offset transact
comment cash posit expect burn rate next
outlin next step on-going patent litig vs
expect freedom oper addit roadblock
question manag
view eptinezumab efficaci profil light promis dataset
vs competitor therapi come recent ph iii public competitor
chang view profil competitor space ligand vs
receptor target approach hepat safeti profil cgrp mab overal
gate step left bla submiss
initi undertaken prepar commerci launch
size salesforc focus launch
may capit potenti delay competitor antibodi give
confid manufactur abl meet capac initi launch
wont run similar delay
look launch competitor therapi year
discuss payer reveal think
price given iv deliveri expect price competitor
therapi year signific would expect price competit
step-through eptinezumab similar subcu hospit administr
potenti partner approach key consider
think partnership global region part overal
expect see updat immunogen data level
confid safeti profil rel other
botox fit broader treatment paradigm price pictur
question manag
comment mbc studi enrol progress
interim efficaci analysi mbc studi power
chanc could read posit
level efficaci think oraxol need achiev order commerci
help us understand rational behind compar oraxol vs iv
paclitaxel compar oraxol pk profil vs iv paclitaxel
abraxan test vs iv paclitaxel circa think
chang real-world practic impact physician view trial result
given prefer weekli schedul
expect ae rate oraxol cohort vs iv
comment patient enrol criteria mbc studi relat
comment prior current effort develop oral taxan tesetaxel
outlin variou path forward discuss agre
fda health author cfda
rational behind lilli collabor oraxol ramucirumab gastric
cancer could leverag futur
high level view commerci opportun oraxol vs abraxan
vs iv paclitaxel given latter wide use decad afford
gener
studi design compar oraxol vs abraxan oraxol
show superior vs iv paclitax think uptak vs abraxan
even oraxol show superior vs iv paclitaxel strategi compet
abraxan us market
view market opportun ak unmet need
would price strategi vs current avail therapeut
updat us potenti timelin ak studi could
read
comment outlook specialti pharma api busi
expect steadi growth might affect if/when sodium
bicarbon inject import shortag
question manag
view price evolv import celg adapt
chang environ myeloma price increas meaning
degre contribut revenu growth what right way
think go forward
seen chang front-lin myeloma treatment paradigm sinc
present dara vmp data ex-u us sens
place dara combo may futur treatment paradigm particularli
velcad gener
comfort stabil contract agreement struck
otezla last year kind traction expect year
see stabil gross/net addit growth driver could see
otezla room ex-u adopt degre inflect qd dose could provid etc
ulcer coliti base ph ii data might otezla fit ibd
extent delay ozanimod uc enrol function increasingli
competit ibd landscap vs broader initi popul earlier-stag patient
target initi enhanc enrol gone
latest base case expect ozanimod label believ
suffici safeti data could potenti elimin need first-dos cv
monitor ms label
addit diversif consid take near term
would either augment add recent acquisit addit acquisit
take transform approach vs focu partnerships/option agreement
therapeut area focus import distribut
partnership model secur futur growth chang view
recent approach histor templat still prefer approach
go forward move iter model better enhanc success
view upcom markman hear gaug potenti engag
substanti could margin expans prior pomalidomid revlimid
generic what right way think preserv margin lt
product go gener
would take learn remarc relev studi
handicap potenti approach interpret augment data might
differ settings/regimen enabl success augment
saw setback pipelin commerci correspond
adjust long-term guidanc -- learn took
develop better inform approach long-term financi target
set anyth refin done differ move forward
question manag
initi sale expect sale helpisav-b expect
sale ramp
timelin formulari negoti differ vaccin
still activ search heplisav-b commerci partner
level confid heplisav-b receiv posit recommend
go upcom acip meet impact would posit neg
recommend commerci prospect influenc
recommend long-term sale opportun opportun
prefer statu vs current standard care hbv vaccin
enrol track studi breadth data expect
see studi vs breadth prior data cut
plan present head/neck cancer data includ alongsid
separ addit melanoma data
gaug efficaci vs treatment develop
epacadostat/keytruda opdivo/yervoy treatment use separ
popul biomark data would indic potenti high
respond could safeti differenti
expect data vs prior data cut degre
lower respons would accept given high bar set prior data cut
what bar benchmark like activ
statu asthma program
think opportun would inhal
treatment fit treatment paradigm etc
question manag
see hcv market share price continu evolv new
equilibrium might expect broader payer discuss unfold
us ex-u hcv market
current royalti structur expect royalty-ti adjust
come year best way model go forward especi
extent mavyret sale driven pent-up demand among
patient confid sale expect
walk recent present ph nash data aasld
nashtag confer specif given chang
somewhat variabl diurnal confid dose select ph ii
use benchmark pd translat phase phase ii
went decis pursu shorter lft signal-find studi
nash rather longer biopsy-driven trial necessari would
subsequ biopsy-driven trial prior move registr studi
would fastest potenti timelin conduct
given fxr mechan action make confid similar
safeti effect cholestat patient seen icpt bile acid mimet
observ pbc patient could differ dose half-lif potenc fxr
address
talk mechan action might confer
higher barrier resist rsv vs rsv approach preclin
cellular toxic data compar prior development protein target therapi
quickli could challeng studi produc readout start schedul
applic would proof concept data challeng studi go-
forward popul naturally-infect pt
patient popul initi focu rsv develop base
potenti market opportun could differ popul affect clinic
expect hbv candid enter clinic
consider went select hbv candid
look easl
question manag
compani thought overal cabo market opportun rcc
launch progress follow approv
nuanc base cabosun vs compar
dataset could help cabo
think opdivo/yervoy broadli use limit patient
data date seem indic measur orr os larg driven
patient
thought potenti patient switch opdivo/yervoy cabo
given high toxic lead discontinu rate
market research contextu physician familiar manag cabo
vs potenti manag opdivo/yervoy immune-rel
envis scenario cabo becom prefer option patient
high diseas burden requir rapid respons
relat tki io combo see issu hindranc cabo seen
prefer combin agent vs pure play potent vegf tki like inlyta
cabo enter rcc affect promis traction
envis scenario cabo becom agent choic might
posit support
thought futur treatment paradigm tki combin
io cabo fare vs tki
view competit cabo profil vs stivarga io given
might cabo safeti profil physician inexperi manag
potenti impact commerci uptak
view cabo market opportun vs stivarga given label
restrict use post-nexavar patient percentag patient actual
candid actual receiv nexavar
view speak immatur natur market
anticip futur treatment paradigm also shift toward tki
io combo see cabo posit
lcm initi cabo excit
see cabo io combo fit rapidli evolv bladder cancer
see bar move forward indic
speak expect drug light current novarti emerg
array competit brafi/meki melanoma segment
view cotel data date read-through market
opportun
thought regard cotel io potenti abil turn cold
tumor hot per data
speak strategi grow pipelin intern discoveri vs
see stay within sweet spot target cancer drug develop
potenti expand modal
specif target area excit see promis
question manag
grow backlog yescarta patient intend help patient
reimburs hurdl expect launch ramp look
start year balanc need train safeti
import expand physician center experi establish barrier
entri
quickli technolog cell design lab integr program car-t
program next-gen cell therapi asset look toward
view import potenti outpati manag futur
car-t
biktarvi affect current market dynam anticip
cannib current share vs expans share notabl
element drug profil label
expect biktarvi launch trajectori similar taf base
therapi long-term adopt curv degre would expect
bictegravir take share triumeq see market respect
physician reaction recent dolutegravir liver side effect think
affect treatment pattern guidelin long-term
think margin expansion/contract given busi shift hiv
cellular therapi
addit area oncolog includ cellular therapi examin
potenti bd complement recent kite cdl acquisit area
remain ripe bd outsid oncolog gene-edit what specif
intrigu degre repatri abil affect flexibl pursu
expans prep europ on-going area focu done
increas usag ex-u payer ex-u interact suggest
amen use descovi prep data posit
given faster expect enrol timelin nash anticip
market access vs broader competit landscap addit data
nash portfolio year critic shape go-forward plan includ
view differenti characterist filgotinib
convinc venou thromboembol observ program
drug specif class effect
expect vosevi big revenu opportun
vosevi consid degre patient fail hcv antiretrovir
engag alreadi healthcar system recent high growth rx data
reflect real-world adopt
question manag
describ scientif basi mainten set practic
consider choos set broad mainten set
synovi sarcoma patient would
plan continu develop non-mainten set
manufactur regulatori activ need undertak prior get
ph iii studi run
pursu enrol optim strategi enrol
patient biomark may ideal respond
given promis biomark data random ph ii studi
clariti might appropri cutoff phase popul
percentag follicular nhl patient posit express commonli
found tumor type
opportun expedit approv combin
atezolizumab refractori sarcoma set expect see
updat data sens regulatori bar
contextu orr observ pembro nhl rel
studi suggest orr inhibitor alon much contribut respons
rate would expect radiat make
latest view potenti path forward next step
technolog advanc enabl multi-antigen construct popul
could potenti target antigen focus progress
toward clinic
might see initi data prime-boost-pul approach
look
question manag
pleas provid insight regard confid level
futil analysi forward expect
provid color patient demograph forward similar
differ run-in studi inform confid cross
provid updat tripl combin therapi arm mirvetuximab
avastin carboplatin view combo posit vs evolv
increasingli crowd ovarian market
look see forward ii combin trial particularli
keytruda cohort monotherapi shown respons rate
area see mirvetuximab advantag parp inhibitor
platinum sensit set shown promis mainten therapi
steadi stream data relat mirvetuximab combin
year pleas remind us cadenc
inbound interest licens coltuximab
kadcyla royalti right sold tssp back receiv
royalti tssp receiv project
priorit potenti indic would like pursu
bpdcn aml program
expect see next data updat
provid updat trial
help us understand rational potenti cost-sav afford
question manag
top-lin readout reflect final data analysi potenti
interim much detail would expect provid top-lin press releas vs
present meet expect specif number
much use nivo/ipi real world given safeti profil base
would consid bar potenti commerci success
relative/absolut improv studi
right way interpret expect timelin potenti echo-
epacadostat melanoma readout consid potenti mix factor tumor
microenviron mutat statu statu express level
treatment-nav popul could see longer median pembro alon
set histor compar
view magnitud benefit seen implic
epacadostat indic
epacadostat fail melanoma would affect invest epacadostat
indic would affect priorit pipelin
could elabor plan biomark identifi
put biomark use stratifi criteria futur studi could identifi
biomark incorpor on-going studi sub-group analys conduct
would set analys replic across epacadostat
think bar success studi epacadostat lung cancer given
competit environ
view physician regulatori percept jak inhibitor ra
level confid safeti baricitinib base total
insight baricitinib launch strong germani rel
area
could broad use baricitinib dose ex-u patient lack appar
safeti issu use supplement nda
asset pipelin strongest rational combo w/
develop priorit
much clinic develop need done w/ slot
combo studi
question manag
key featur advantag platform enabl optim
target enhanc io deliveri
walk us work celectra technolog syncon
plasmid confer potenti advantag approach
character size unmet need hpv-relat pre-canc
limit leep procedur
given presenc approv hpv vaccin think potenti
opportun market within current prospect
remind us key learn result phase ii studi
find give confid inform reveal reveal ii cervic dysplasia
phase program progress latest enrol
track toward oper goal estim timelin
reveal reveal ii run parallel think
sequenc design program eye potenti readout
phase ii vulvar dysplasia program progress latest plan
anal dysplasia clinic studi
describ inovio overal approach io combin strategi
partnership differenti versu combo approach underway
io platform partnership walk us latest develop construct
timelin medimmune-partn program hpv-relat
head neck cancer genentech-partn program bladder
cancer roche-partn program gbm
put inovio broader vaccin platform context asset
pipelin term fit focu valu creation
data phase studi hbv expect quarter
look think advanc develop asset
commerci readi current celectra deliveri devic aspect
technolog focu on-going enhanc
key valu driver inovio pipelin next month
question manag
given array schizophrenia treatment market see
lumateperon potenti fit current treatment paradigm key
element agent safeti and/or efficaci profil would critic
differenti market
recent complet switch studi tell us activ
lumateperon would expect schizophrenia patient switch
antipsychot see stabl panss score week anticip abl
use safety/efficaci data studi upcom nda submiss
could talk long-term safeti studi lumateperon mani
patient current enrol studi group patient
switch studi even though primarili safeti studi concurr
efficaci evalu take place result studi incorpor
on-going regulatori discuss file
level detail expect receiv fda feedback come
pre-nda meet specifi potenti path forward regulatori
approv lumateperon view like agenc would directli
endors potenti file base one phase ii one phase studi and/or
whether approv still possibl despit one neg ph iii studi meet
schedul expect detail meet disclos
could elabor caus high rate placebo respons schizophrenia
issu disproportion affect schizophrenia studi common
behavior clinic studi role outlier site play placebo respons
requir conduct addit phase studi schizophrenia
anyth youv learn previou three clinic studi could help
minim placebo respons
three concurr phase studi lumateperon bipolar disord could
elabor decis enrol three concurr bipolar studi
differ dose inclus criteria patient popul length studi endpoint
use studi inform efficacy/safeti lumateperon
bipolar disord could tell us cadenc trial readout
big market opportun dementia-associ agit could compar
opportun bipolar/schizophrenia directli one map cognit
effect seen small ph ii studi geriatr subject dementia pt potenti
psychiatr indic lumateperon could potenti
util
treatment parkinson disease- inhibit mechan ever
explor parkinson differenti previou pde inhibitor
could potenti use conjunct l-dopa would expect
two mechan complementari given neuroprotect
mechan would expect use earli possibl onset
parkinson could neuroprotect mechan applic kind
question manag
elabor revers ph iii trial design nash patient cirrhosi
compar therapi could potenti augment
label timelin estim commerci opportun
patient popul determin dose regimen studi
initi feedback physician follow label updat
tone regard potenti concern prescrib habit chang vs label
trend see new patient start refil
learn respect target physician educ goalpost
look toward on-going re-educ effort valid confid
script trajectori re-acceler
post-market experi ocaliva independ analys conduct
on-going pbc clinic trial reassur safeti efficaci pbc
enrol progress full regener dataset beyond interim
cohort signific trial monitor adjust made optim
safeti trial
think price nash vs maintain orphan drug premium
mani think accur non-invas method diagnosi nash critic
identifi patient ultim success treatment view
see nash diagnosi evolv come year
think life cycl manag ocaliva could
anticip updat highli select fxr asset pipelin
commerci aspect nash market plan examin
latest think develop psc potenti path forward
indic
question manag
see selinexor potenti fit rel bcma car-t
approach mm space given broad interest anti-bcma mechan
think selinexor could potenti use supplement bcma-bas therapi
commerci potenti less two year away step take
prepar selinexor launch
latest think bar potenti acceler approv penta-
refractori mm regulatori view evolv see path
forward sel/pom pom-refractori patient given solid respons rate
level confid selinexor side effect mitig dose
optim manag tpo agent
level confid abil enrol boston studi given
vel-dex backbon emerg altern regimens/combo refractori
data interim readout ph iii boston studi disclos might
crossov boston studi potenti confound abil demonstr os
contextu revlimid combo data stomp trial given
rel earlier-stag patient popul enrol studi
expect ph iii liposarcoma trial begin enrol europ
mani patient enrol us vs eu
base earli result quad- penta- refractori mm see
earli signal differenti selinexor either efficaci safeti profil
partner ono play role develop
regulatori commerci bar view expand sadal dlbcl
out-licens fit broader develop strategi
plan licens non-oncolog pipelin asset move forward
factor import decis out-licens
advantag out-licens asset partnership
question manag
expect ph ii trial herceptin mbc mcla-
endocrin therapi fulli enrol given number site
across us europ expect one arm studi enrol faster
event one arm slow enrol plan read top-lin
result arm
total patient arm studi kind efficaci signal
trial power detect intern bar magnitud clinic benefit
rate need continu develop indic
see bar success er group given open-label
natur studi number pt and/or efficaci criteria might prompt
report interim result full enrol reach
go no-go decis gastric ovarian cancer
import factor make decis appropri histor exampl
amen partnership develop might
look could optim time
see safeti preliminari efficaci data dose-finding/escal ph
prior cohort expans cr rate aim higher dose
manag balanc efficaci vs prevent dose escal
plan file cta colorect cancer trial
see program differenti
larger trial initi near futur think spend
go
could talk establish partnership simcer could
ind-en studi clinic develop china help support develop
us eu
plan leverag biclon platform develop antibodi
novel antigen antigen combin
question manag
main driver behind strong translarna guidanc
critic assumpt need reach guidanc
initi taken help identifi dmd patient us eu ww
much project translarna growth due increas market penetr
current market vs expans new region
limit factor growth emflaza us patient
physician educ play role
think mean patient weight dose administ emflaza
launch progress expect lower averag patient age balanc
weight gain averag treatment durat increas
physician recept new dmd treatment guidelin publish
lancet recommend emflaza/corticosteroid use younger patient
leverag guidelin improv emflaza uptak
quick anticip recruit sma trial given increasingli
competit landscap spinraza uptak
given uniqu mechan action think could potenti
use combin market sma treatment experiment gene therapi
treatment could enhanc activ oligo-bas exon skipper
spinraza distinct site action
potenti current sma trial use pivot studi given high
unmet need popul ema fda hint certain number
patient length patient follow would requir registr
potenti use pool safeti efficaci data across sunfish firefish
jewelfish
receiv regular communication/ updat trial year data
accru enrol patient updat present major medic
question manag
recent data updat posit efficaci signal soliris-nav
patient transfus independ switch patient maintain data
transfusion-depend switch inadequ respond remain mix
think reason differ efficaci differ popul
still plan pursu transfusion-depend switch inadequ respond
popul would path forward
see compet soliri and/or carv market
opportun especi given efficaci transfusion-depend switch inadequ
respond compris pnh popul exhibit greatest unmet
factor size compar arm timelin endpoint locat site etc
plan discuss fda upcom meet
preliminari thought regard requir
cost estim run studi seek ex-u
view physician/pati prefer qd sc therapi vs
think real-world complianc could affect efficaci
price strategi competit and/or soliri
also push forward sc formul think
impact market potenti inform develop strategi
thought regard competitor base report efficaci
safeti data
complement-medi diseas
could provid us color timelin program
gmg ahu ln
studi gmg target refractori gmg patient rather earlier
stage treatment larger popul could explain rational behind
difficulti see get approv set
price strategi think would enabl reimburs vs
convent soc earlier line gmg treatment
could posit two differ indic orphan vs
strategi timelin oral inhibitor program
addit clinic program anticip
help us understand merck collabor econom
occur program move clinic stage
activ look partnership leverag drug discoveri platform
type collabor look
question manag
view adcetri approv prospect broad label stage hl
think fda could narrow adcetri hl label stage risk stratif
tumor burden given pronounc hr seen
thought regard fda potenti provid expand label
could spa agreement place fda impact
increment delta seen
think csf prophylaxi univers use delta could
achiev meaning separ
even broad label grant think adcetri commerci opportun
impact see scenario guidelin recommend stringent
vs label
impact sellabl adcetri benefit limit subsequ therapi
etc especi commun physician
regulatori outlook eu look like
adcetri indic
view ultim market opportun ctcl given exist off-label use
much anticip util increas recent approv sale
adcetri run-in studi mtcl drive confid read-out
help us understand adcetri valu proposit mtcl compar contrast
hl
lcm initi adcetri dlbcl excit
enrol go post-checkpoint studi
speak rational behind combin checkpoint plan
path forward initi might look like
progress plan cervic cancer trial start
strategi plan pursu move tv earlier line therapi
combin checkpoint avastin etc could path forward look like
determin gate factor toward
progress program later stage
focu shift toward combin checkpoint still see path
market monotherapi
view rel posit
help us understand rational behind casc acquisit might
inform bd strategi go forward
view tucatinib rel posit vs oral tki
plan develop tucatinib beyond mbc
question manag
pleas provid updat propos outcomes-bas reimburs
model us addit pbm shown interest
contract final
pleas provid updat regard progress obtain best
price exclus waiver import market access strategi
nv like pursu similar outcomes-bas reimburs model ex-u
luxturna approv broad label encompass ird
discuss initi progress regard patient identif mani
addit patient think us ex-u
proport patient current identifi
genet test provid updat genet test program
idyourird progress
think us launch luxturna particular cadenc new
patient start first year launch
thought potenti need re-dos patient
current plan work investig possibl
think appar variabl lack dose-respons
seen recent data
confound factor led patient level unexplain spike
might fviii level chang addit follow-up
steroid use requir addit patient trigger re-
evalu trial protocol
 anticip timelin chang given potenti
necess long-term follow-up
what go/no-go hurdl move hemophilia phase could
potenti timelin
regulatori path forward hemophilia could potenti phase studi
safe and/or efficaci level factor viii express especi given
lead normal potenti supra-norm fviii express
think market opportun hemophilia especi given
possibl multipl gene therapi like second later market
process transfer hemophilia program
expect transfer complet
expect phase trial initi timelin conduct
studi
compar contrast approach hemophilia competitor
provid updat regard time choroideremia read-out
provid color regard expect addit enrol
earlier stage diseas could drive treatment benefit vs mix data
seen date later stage patient
hurdl move choroideremia program forward
could compar contrast program competitor nightstar
lori calvasina head us equiti strategi
becton dickinson compani nyse sector perform
